Switching from injectable platform therapies to oral first-line therapies in patients with clinically stable RRMS does not increase the risk of disability accumulation, research shows. A study of more than 3,000 patients in the Danish Multiple Sclerosis Registry compared outcomes in those who switched from interferon-β or glatiramer acetate to either dimethyl fumarate (DMF) or ...
No downside to switching to oral MS therapies: study
By Mardi Chapman
22 Feb 2021